type of intervention
Prospective cohort study
recruitment status
Recruiting
region
NSW, QLD, VIC, WA
type of ms
Primary progressive MS, Relapsing MS, Relapsing remitting MS, Secondary progressive MS
COVID-19 vaccines are now being rolled out. Many people living with MS are treated with drugs that affect their immune system, and there is not a lot of specific data relating to the administration of the COVID-19 vaccines to a person with MS who is treated for their disease. This is a multi-center study to determine the COVID-19 vaccine immunogenicity and to assess the protection given by vaccines in people living with MS.
– Diagnosed Multiple Sclerosis according to 2017 McDonald criteria
– Treatment by any TGA-approved Disease Modifying Therapy (DMT) for MS, e.g. ocrelizumab, alemtuzumab, natalizumab, fingolimod, cladribine, beta-interferon, copaxone, dimethylfumarate, ofatumumab, siponimod, glatiramer acetate.
– Recipient of COVID-19 vaccine (Pfizer, Astra Zeneca, or Novavax).
– Is able to give consent
Non-English speaking
May 2021
Fabienne Brilot-Turville, fabienne.brilot@sydney.edu.au
NSW/VIC/QLD/WA
Yes
21/06/2021
